EA201490809A1 - Способы и композиции для лечения неэффективного эритропоэза - Google Patents

Способы и композиции для лечения неэффективного эритропоэза

Info

Publication number
EA201490809A1
EA201490809A1 EA201490809A EA201490809A EA201490809A1 EA 201490809 A1 EA201490809 A1 EA 201490809A1 EA 201490809 A EA201490809 A EA 201490809A EA 201490809 A EA201490809 A EA 201490809A EA 201490809 A1 EA201490809 A1 EA 201490809A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
erythropoesis
compositions
effective
treatment
Prior art date
Application number
EA201490809A
Other languages
English (en)
Other versions
EA034563B1 (ru
Inventor
Джасбир СИХРА
Роберт Скотт Пирсалл
Равиндра КУМАР
Нага Венката Саи Раджасекхар Сурагани
Original Assignee
Акселерон Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акселерон Фарма, Инк. filed Critical Акселерон Фарма, Инк.
Publication of EA201490809A1 publication Critical patent/EA201490809A1/ru
Publication of EA034563B1 publication Critical patent/EA034563B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам лечения неэффективного эритропоэза у пациента, включающим введение пациенту полипептида ActRIIB, по меньшей мере на 90% идентичного последовательности из 109 аминокислот SEQ ID NO:1, где указанный полипептид содержит кислую аминокислоту в положении 79.
EA201490809A 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией EA034563B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis

Publications (2)

Publication Number Publication Date
EA201490809A1 true EA201490809A1 (ru) 2014-09-30
EA034563B1 EA034563B1 (ru) 2020-02-20

Family

ID=48141315

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090053A EA202090053A3 (ru) 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза
EA201490809A EA034563B1 (ru) 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202090053A EA202090053A3 (ru) 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза

Country Status (13)

Country Link
US (4) US20130243743A1 (ru)
EP (3) EP3520805B1 (ru)
JP (4) JP6092883B2 (ru)
KR (4) KR20200019261A (ru)
CN (3) CN107693776A (ru)
AU (4) AU2012326207B2 (ru)
BR (3) BR122019023174B1 (ru)
CA (1) CA2852683A1 (ru)
DK (1) DK3520805T3 (ru)
EA (2) EA202090053A3 (ru)
ES (2) ES2741477T3 (ru)
HK (3) HK1203413A1 (ru)
WO (1) WO2013059347A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (zh) 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ME02333B (me) 2007-02-09 2013-04-30 Acceleron Pharma Inc FARMACEUTSKE SMEŠE KOJE SADRŽE AKTIVIN-ActRIIA ANTAGONISTE I NJIHOVA UPOTREBA U PREVENCIJI ILI LEČENJU MULTIPLOG MIJELOMA
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX2011013172A (es) 2009-06-08 2012-04-02 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
WO2015143403A1 (en) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
AP2016009549A0 (en) * 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP4233889A3 (en) * 2014-12-03 2023-10-11 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
WO2016183280A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
US10548976B2 (en) * 2015-05-20 2020-02-04 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
KR20180096645A (ko) 2015-11-23 2018-08-29 악셀레론 파마 인코포레이티드 눈 질환의 치료 방법
WO2018067874A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN111050770A (zh) * 2017-06-14 2020-04-21 细胞基因公司 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
AU716893B2 (en) 1995-04-11 2000-03-09 General Hospital Corporation, The Reverse two-hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
KR20050056247A (ko) * 2002-10-15 2005-06-14 셀진 코포레이션 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI748373B (zh) * 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
CN102655872B (zh) * 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Also Published As

Publication number Publication date
EA034563B1 (ru) 2020-02-20
JP2017101060A (ja) 2017-06-08
HK1252940A1 (zh) 2019-06-06
AU2017201580A1 (en) 2017-03-30
EP2797620A1 (en) 2014-11-05
DK3520805T3 (da) 2021-04-19
EA202090053A3 (ru) 2020-06-30
US20170137791A1 (en) 2017-05-18
EA202090053A2 (ru) 2020-04-30
KR20200019261A (ko) 2020-02-21
CN107693776A (zh) 2018-02-16
KR20140084211A (ko) 2014-07-04
EP3520805A1 (en) 2019-08-07
AU2012326207A1 (en) 2014-05-15
AU2018247262A1 (en) 2018-11-01
ES2869168T3 (es) 2021-10-25
AU2020286229A1 (en) 2021-01-07
BR122019023166B1 (pt) 2021-02-23
BR112014009528B1 (pt) 2020-12-29
BR112014009528A2 (pt) 2017-05-09
BR122019023174B1 (pt) 2021-02-23
JP2020186277A (ja) 2020-11-19
JP6383821B2 (ja) 2018-08-29
CN107837390A (zh) 2018-03-27
KR20220075438A (ko) 2022-06-08
JP2018165287A (ja) 2018-10-25
KR102079482B1 (ko) 2020-02-19
JP2014530253A (ja) 2014-11-17
BR112014009528A8 (pt) 2019-12-10
CA2852683A1 (en) 2013-04-25
CN103987403A (zh) 2014-08-13
AU2012326207B2 (en) 2016-12-15
KR20190105113A (ko) 2019-09-11
ES2741477T3 (es) 2020-02-11
AU2018247262B2 (en) 2020-12-24
AU2017201580B2 (en) 2018-07-12
EP3520805B1 (en) 2021-03-10
HK1250341A1 (zh) 2018-12-14
JP6092883B2 (ja) 2017-03-08
US20170327800A1 (en) 2017-11-16
EP2797620B1 (en) 2019-04-24
JP6796626B2 (ja) 2020-12-09
HK1203413A1 (en) 2015-10-30
EP3875104A1 (en) 2021-09-08
US20130243743A1 (en) 2013-09-19
WO2013059347A1 (en) 2013-04-25
CN103987403B (zh) 2017-12-01
EP2797620A4 (en) 2015-05-20
US20210207107A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX2014000373A (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b.
IN2014KN01715A (ru)
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
IN2014KN01713A (ru)
IN2014KN01714A (ru)
IN2014KN01716A (ru)
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
MY167232A (en) Polypeptides binding to human complement c5
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
EA201391387A1 (ru) Нейропротекторные пептиды
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM